A Long-Term Follow-Up Study Of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products

Overview

About this study

This protocol is to ensure consistent long-term follow-up for delayed safety events in participants who received A2 Bio gene therapy (GT) products.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:
1. Received any amount of A2 Bio GT product on a previous A2 Bio interventional study
2. Able to provide written informed consent for this long-term follow-up study
3. Able to comply with study requirements

Exclusion Criteria:
1. There are no specific exclusion criteria for this study

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 7/24/2025. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Julian Molina

Closed-enrolling by invitation

What is this? (?)
"Close"
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available
.
CLS-20597114

Mayo Clinic Footer